Navigation Links
Investigational anti-restenosis drug pimecrolimus disappoints
Date:3/31/2008

CHICAGO, Ill. (March 31, 2008) A new medication that researchers had hoped would reduce the risk of arterial renarrowing after stenting has turned in a disappointing performance in a multicenter clinical trial, but the multi-reservoir stent that was used to deliver the drug is still considered promising.

Pimecrolimus, an anti-inflammatory medication, was expected to reduce arterial inflammation and, therefore, the overgrowth of scar tissue, or neointimal hyperplasia, that causes in-stent restenosis. Instead, patients treated with pimecrolimus-eluting stents fared far worse than patients treated with stents that delivered a combination of pimecrolimus and paclitaxel, or paclitaxel alone, according to the Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries (GENESIS). Paclitaxel is also an anti-restenosis medication, but it works by inhibiting cell division, rather than by reducing arterial inflammation.

The GENESIS study was terminated early by its sponsors. The data gathered to that point are being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

Despite pre-clinical data suggesting marked efficacy of pimecrolimus in suppressing neointimal hyperplasia, the extent of tissue growth and resulting rates of target vessel revascularization at six months were high in patients treated with this drug, said Stefan Verheye, MD, PhD, co-director of the catheterization laboratories at Antwerp Cardiovascular Center, ZNA Middelheim Hospital, Antwerp, Belgium.

The GENESIS study was als
'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Investigational drug tested for preventing muscle fiber death in muscular dystrophy
2. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
3. New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets
4. UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
5. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
6. MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight
7. Abbotts Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
10. Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract
11. Accentia announces investigational new drug application for Revimmune for refractory MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
... tends to dissuade sleep, and it may be the best r...ccording to latest research reports. The alertness... color of the light they are working under, accord...elonging to the Brigham & Women's Hospital. Ligh...
...g Menopause? Losing your mind? Just pause and read...nual meeting of the International Neuropsychologic...opause might just get a bit unforgettable. That me...membering things! One more of that middle age blue...
...of Connecticut will be contacting police officers,...e Chief if a pandemic influenza were to break out....lso gearing themselves for such a situation. The f...ront while dealing with emergencies. Humanity has ...
...Bill Keevil and Jonathan Noyce, University School ...have reported that Copper metal has antiviral prop...uenza A virus. In an Invitro study on culture plat... Plaque Forming Units (PFU) of Influenza virus alm...
Other Medicine News:Health News:Menopause pauses memory, posing unforgettable problems 2
(Date:10/6/2008)...ildren, parents discussing clinical ...PRNewswire-USNewswire/ -- From asthma and cancer,t...lives and improves their,health and well-being. A ...h (NIH), "Children and Clinical Studies", (http://...fers parents and health,care providers an insider,...
(Date:10/6/2008)...DE Therapy is More Likely to Induce Steroid-Free...ard Immunomodulator, Azathiopr...resented for the first time,from the Phase 3b Stud...modulators and Biologic Therapy (SONIC) may provid...ts with moderate to severe Crohn,s disease.,Accord...
(Date:10/6/2008)...ed for 9:00 AM ET Today -, SEATTLE, Oct. 6 /PRNew...DNDN) announced today that it has completed the pl... double-blind, placebo-controlled IMPACT,(IMmunoth...known as D9902B),clinical trial designed to assess...tive cellular immunotherapy PROVENGE(R) (sipuleuce...
(Date:10/6/2008)...ompany,s Bioabsorbable Stent - Also,Slated for Pre...wire/ -- Data from multiple clinical trials of,the...ous Bio-engineered R,stent, will be presented next...tics symposium, TCT 2008, in Washington, D.C., Ro...cal Center in,Amsterdam will provide a Genous clin...
Breaking Medicine Technology:Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2082 1Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2082 2Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2082 3Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2082 4Medicares Drug Program Enrollment Up Costs Down 10702 1Medicares Drug Program Enrollment Up Costs Down 10702 2Medicares Drug Program Enrollment Up Costs Down 10702 3Genghis Grill Offers Recipes Featuring Heart Healthy Dining Options 10697 1Genghis Grill Offers Recipes Featuring Heart Healthy Dining Options 10697 2Britney Spears 3A Lets Talk About All of Us 10692 1Britney Spears 3A Lets Talk About All of Us 10692 2
...esponse, Health Organizations Unite to Help Educat...e Risk of Other Serious,Health Problems, SEATTLE, ...,report looking at the prevalence and cost of type...three out of five people,(57.9 percent) with type ...health problems commonly associated with the disea...
... YORK, April 10, 2007 /PRNewswire-FirstCall/ -- Im...b Company today,announced that a Phase III study o...therapy) in patients with locally advanced,unresec... its,primary endpoint of improving overall surviva...OG), a cancer,center network sponsored by the Nati...
Other Medicine Technology:First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 2Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 4Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 5Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 6Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 8Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 9
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: